Is intraoperative touch imprint cytology of sentinel lymph nodes in patients with breast cancer cost effective?

Keyphrases

• Patients with Breast Cancer 100%
• Sentinel Lymph Node 100%
• Cancer Costs 100%
• Touch Imprint Cytology 100%
• Lymph Node Sampling 50%
• Large Tumors 20%
• Surgeons 10%
• Metastasis 10%
• Tumor Stage 10%
• Health Status 10%
• Sensitivity Analysis 10%
• Quality-adjusted Life Years 10%
• Decision-analytic Model 10%
• Incremental Cost-effectiveness Ratio 10%
• Node Dissection 10%
• Dominant Strategy 10%
• Node-negative Breast Cancer 10%
• Sentinel Lymph Node Biopsy 10%
• Sentinel Lymph Node Metastasis 10%
• Positive Sentinel Lymph Node 10%
• Cost-sensitive Evaluation 10%
• EQ-5D 10%
• Immediate Feedback 10%
• Surgical Staging 10%
• Clinically Node-negative 10%

Medicine and Dentistry

• Cytotechnology 100%
• Health Care Cost 100%
• Breast Cancer 100%
• Sentinel Lymph Node 100%
• Sensitivity and Specificity 20%
• Tumor 20%
• Surgeon 10%
• Metastatic Carcinoma 10%
• Prevalence 10%
• Cancer Staging 10%
• Base 10%
• Health Status 10%
• Cost-Effectiveness Analysis 10%
• Quality Adjusted Life Year 10%
• Sentinel Lymph Node Metastasis 10%
• Sentinel Lymph Node Biopsy 10%

Nursing and Health Professions

• Breast Cancer 100%
• Cytology 100%
• Sensitivity and Specificity 20%
• Surgeon 10%
• Prevalence 10%
• Base 10%
• Health Status 10%
• Cancer Staging 10%
• Quality Adjusted Life Year 10%
• Incremental Cost-Effectiveness Ratio 10%
• Sentinel Lymph Node Metastasis 10%
• Sentinel Lymph Node Biopsy 10%